Actively Recruiting

Age: 18Years +
All Genders
NCT05991895

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Led by Jinming Yu · Updated on 2023-08-15

5000

Participants Needed

1

Research Sites

153 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China. The study aims to enroll ALK-positive NSCLC patients who have undergone treatment with Iruplinalkib prior to enrollment. Demographic information, medical history, Iruplinalkib-containing treatment regimens, clinical outcomes, adverse events, and related data will be collected for all enrolled patients. As this study is a real-world investigation, treatment procedures, visit schedules, and examinations will be based on the routine clinical practice of physicians. The primary sources of data for this study will mainly consist of patients' routine medical records or healthcare documentation.

CONDITIONS

Official Title

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients willingly contribute their clinical data for this study
  • Patients with ALK-positive non-small cell lung cancer
  • Age 63 18 years
  • Patients who have undergone treatment with Iruplinalkib.
Not Eligible

You will not qualify if you...

  • Known pregnant or lactating females
  • Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis requiring ongoing medical intervention.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shandong Cancer Hospital and Institute

Jinan, Shandong, China

Actively Recruiting

Loading map...

Research Team

J

Jinming Yu, PhD

CONTACT

L

Linlin Wang, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer | DecenTrialz